Opinion|Videos|July 12, 2024
Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
ATTR-CM Incidence, Prevalence Rose Sharply in the US
4
Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS
5